New Phase IIIa data further demonstrate benefits of liraglutide in obesity

Positive new data from the Phase IIIa SCALE Obesity and Prediabetes trial were presented today at Obesity Week 2014, the 2nd Annual Congress of The American Society for Metabolic and Bariatric Surgery and The Obesity Society.

The study investigated liraglutide, the active ingredient of Danish insulin giant Novo Nordisk’s blockbuster diabetes drug Victoza at a higher dose in the management of obesity. The drug (intended trade name Saxenda) is already under regulatory review for a weight loss indication, and recently gained a favorable recommendation from a US Food and Drug Administration advisory panel (The Pharma Letter September 12).

Study details